[Skip to Content]
[Skip to Content Landing]
Views 940
Citations 0
Comment & Response
February 19, 2014

Short-Acting β-Blocker Administration in Patients With Septic Shock

Author Affiliations
  • 1Oxford Heart Centre, Oxford University Hospitals, Oxford, England
  • 2Department of Anesthesiology and Intensive Care, Philipps University, Marburg, Germany
JAMA. 2014;311(7):736-737. doi:10.1001/jama.2014.315

To the Editor In a large randomized clinical trial of the use of a β-blocker (esmolol) in patients with severe septic shock, Dr Morelli and colleagues1 demonstrated the ability of esmolol to reduce heart rate. The use of esmolol was associated with a reduction in norepinephrine and fluid requirements and an increase in stroke volume, systemic vascular resistance, and left ventricular stroke work indices. These cardiovascular effects were not only associated with improved respiratory function and metabolic parameters but also with lower 28-day mortality.

First Page Preview View Large
First page PDF preview
First page PDF preview